HY 0001a
Alternative Names: HY-0001; HY-0001aLatest Information Update: 23 Dec 2025
At a glance
- Originator Sichuan Huiyu Pharmaceutical
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Dec 2025 Sichuan Huiyu Pharmaceutical withdraws prior to enrolment the phase I/II trial for Solid tumours (Late-stage diseases, Metastatic-diseases) in China (IV) due to a strategic amendment to the protocol (NCT07069062)
- 07 Jul 2025 Sichuan Huiyu Pharmaceutical plans a phase I/II trial for Solid tumours (Late-stage diseases, Metastatic-diseases, Second-line or greater therapy) in China in July 2025 (IV) (NCT07069062)
- 25 Apr 2025 Preclinical trials in Cancer in China (Parenteral) prior to April 2025